In vitro characterisation of BF227 binding to α-synuclein/Lewy bodies

European Journal of Pharmacology

Volumn 617, Issue 1-3, 2009, Pages 54-58

  Fodero Tavoletti, Michelle T ^a,b,c   Mulligan, Rachel S ^d   Okamura, Nobuyuki ^c   Furumoto, Shozo ^c   Rowe, Christopher C ^d   Kudo, Yukitsuka ^c   Masters, Colin L ^c   Cappai, Roberto ^a,b,c   Yanai, Kazuhiko ^c   Villemagne, Victor L ^a,c,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c TOHOKU UNIVERSITY   (Japan)

^d AUSTIN HEALTH   (Australia)

Author keywords

synuclein; A (amyloid ); BF227; Dementia with Lewy bodies; Imaging; Positron emission tomography

Indexed keywords

2 [2 (2 DIMETHYLAMINOTHIAZOL 5 YLE)THENYL] 6 [2 (FLUORO)ETHOXY]BENZOXAZOLE; 2 [2 (2 DIMETHYLAMINOTHIAZOL 5 YLE)THENYL] 6 [2 (FLUORO)ETHOXY]BENZOXAZOLE F 18; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BENZOXAZOLE DERIVATIVE; BF 226; BF 227; BIOLOGICAL MARKER; CARBON 11; LIGAND; PITTSBURGH COMPOUND B C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN HOMOGENATE; BRAIN TISSUE; CONTROLLED STUDY; DRUG BINDING; DRUG SELECTIVITY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEWY BODY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENILE PLAQUE; TISSUE SECTION;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BENZOXAZOLES; BRAIN; FLUORINE RADIOISOTOPES; HUMANS; IMMUNOHISTOCHEMISTRY; LEWY BODIES; LEWY BODY DISEASE; PEPTIDE FRAGMENTS; PROTEIN BINDING; SUBSTRATE SPECIFICITY; THIAZOLES;

EID: 68549085069     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.06.042     Document Type: Article

References (19)

1. Agdeppa E.D., Kepe V., Liu J., Flores-Torres S., Satyamurthy N., Petric A., Cole G.M., Small G.W., Huang S.C., and Barrio J.R. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J. Neurosci. 21 (2001) RC189
2. Boxer A.L., Rabinovici G.D., Kepe V., Goldman J., Furst A.J., Huang S.C., Baker S.L., O'Neil J.P., Chui H., Geschwind M.D., Small G.W., Barrio J.R., Jagust W., and Miller B.L. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology 69 (2007) 283-290
3. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003) 197-211
4. Bresjanac M., Smid L.M., Vovko T.D., Petric A., Barrio J.R., and Popovic M. Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro. J Neurosci 23 (2003) 8029-8033
5. Cappai R., Leck S.L., Tew D.J., Williamson N.A., Smith D.P., Galatis D., Sharples R.A., Curtain C.C., Ali F.E., Cherny R.A., Culvenor J.G., Bottomley S.P., Masters C.L., Barnham K.J., and Hill A.F. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB. J. 19 (2005) 1377-1379
6. Culvenor J.G., McLean C.A., Cutt S., Campbell B.C., Maher F., Jakala P., Hartmann T., Beyreuther K., Masters C.L., and Li Q.X. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am. J. Pathol. 155 (1999) 1173-1181
7. Fodero-Tavoletti M.T., Smith D.P., McLean C.A., Adlard P.A., Barnham K.J., Foster L.E., Leone L., Perez K., Cortes M., Culvenor J.G., Li Q.X., Laughton K.M., Rowe C.C., Masters C.L., Cappai R., and Villemagne V.L. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J. Neurosci. 27 (2007) 10365-10371
8. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. neurol. 55 (1996) 259-272
9. Goedert M., and Spillantini M.G. A century of Alzheimer's disease. Science. (New. York,. N.Y. 314 (2006) 777-781
10. Klunk W.E., Debnath M.L., and Pettegrew J.W. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol. Aging. 16 (1995) 541-548
11. Klunk, W.E., Engler, H., Nordberg, A., Bacskai, B.J., Wang, Y., Price, J.C., Bergstrom, M., Hyman, B.T., Langstrom, B., Mathis, C.A., 2003. Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clinics of North America 13, 781-789, ix.
12. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., and Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 55 (2004) 306-319
13. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., and Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25 (2005) 10598-10606
14. Kudo Y., Okamura N., Furumoto S., Tashiro M., Furukawa K., Maruyama M., Itoh M., Iwata R., Yanai K., and Arai H. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med. 48 (2007) 553-561
15. Mathis C.A., Wang Y., Holt D.P., Huang G.F., Debnath M.L., and Klunk W.E. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Medicinal. Chem. 46 (2003) 2740-2754
16. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., and Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005) 1863-1872
17. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N., Ballard C., de Vos R.A., Wilcock G.K., Jellinger K.A., and Perry R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 47 (1996) 1113-1124
18. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., and Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 68 (2007) 1718-1725
19. Trojanowski J.Q. Emerging Alzheimer's disease therapies: focusing on the future. Neurobiol. Aging. 23 (2002) 985-990